Migalastat (Galafold®) for the treatment of Fabry's disease

Zorginstituut Nederland carried out an assessment of whether, based on the criteria of the Medicines Reimbursement System (GVS), the medicine migalastat (Galafold®) is interchangeable with any other product that is included in the GVS.